169 related articles for article (PubMed ID: 12350511)
1. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.
Nagakawa O; Furuya Y; Fujiuchi Y; Fuse H
Urology; 2002 Sep; 60(3):527-30. PubMed ID: 12350511
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
5. Pro-Gastrin Releasing Peptide: A New Serum Marker for Endometrioid Adenocarcinoma.
Kiseli M; Caglar GS; Yarci Gursoy A; Tasci T; Candar T; Akincioglu E; Pabuccu EG; Boran N; Tulunay G; Umudum H
Gynecol Obstet Invest; 2018; 83(6):540-545. PubMed ID: 29898448
[TBL] [Abstract][Full Text] [Related]
6. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma.
Inaji H; Komoike Y; Motomura K; Higashiyama M; Ohtsuru M; Funai H; Kasugai T; Koyama H
Oncology; 2000 Aug; 59(2):122-5. PubMed ID: 10971170
[TBL] [Abstract][Full Text] [Related]
7. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
Huang Z; Xu D; Zhang F; Ying Y; Song L
Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
[TBL] [Abstract][Full Text] [Related]
8. Serum pro-gastrin-releasing peptide (31-98) in prostatic diseases.
Yashi M; Ishikawa S; Tokue A
Urology; 2003 Jul; 62(1):198-9; author reply 199. PubMed ID: 12837468
[No Abstract] [Full Text] [Related]
9. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
12. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
13. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
14. Serum ceruloplasmin as a marker in prostate cancer.
Fotiou K; Vaiopoulos G; Lilakos K; Giannopoulos A; Mandalenaki K; Marinos G; Koritsiadis G; Sourdis J; Konstantinidou E; Konstantopoulos K
Minerva Urol Nefrol; 2007 Dec; 59(4):407-11. PubMed ID: 17947957
[TBL] [Abstract][Full Text] [Related]
15. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
17. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients.
Nakahama H; Tanaka Y; Fujita Y; Fujii M; Sugita M
Respirology; 1998 Sep; 3(3):207-10. PubMed ID: 9767622
[TBL] [Abstract][Full Text] [Related]
19. Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide.
Yashi M; Muraishi O; Tokue A
BJU Int; 2000 Dec; 86(9):1091-2. PubMed ID: 11119109
[No Abstract] [Full Text] [Related]
20. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]